{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.03","statisticalComment":"Two-sided significance level = 0.05","statisticalMethod":"t-test, 2 sided"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-1.68","upperLimit":"-0.45","value":"-1.06"},{"groupId":"OG001","lowerLimit":"-0.68","upperLimit":"0.24","value":"-0.22"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"69"}],"units":"Participants"}],"description":"Calculated as treatment value - baseline value. HPV DNA was assessed by tumor-tissue modified viral (TTMV) testing.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cisplatin: 40 mg/m2 IV (intravenously) weekly for 6 weeks\n\nIMRT 6 weeks: Intensity-modulated radiation therapy (IMRT), 30 fractions over 6 weeks, 5 fractions per week, 2 Gray per fraction to total dose of 60 Gy","id":"OG000","title":"IMRT 6 Weeks + Cisplatin (Arm 1)"},{"description":"IMRT 5 weeks: Intensity-modulated radiation therapy (IMRT), 30 fractions over 5 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 60 Gy","id":"OG001","title":"IMRT 5 Weeks (Arm 2)"}],"paramType":"MEAN","populationDescription":"Eligible patients with baseline and during treatment HPV DNA values.","reportingStatus":"POSTED","timeFrame":"Baseline and during treatment (obtained after 20 Gy of radiotherapy and before 28 Gy, approximately between day 10 and 14)","title":"Change in Number of HPV DNA Fragments/mL (Copy Number) From Baseline to During Treatment (HPV DNA Rate Decline)","type":"SECONDARY","unitOfMeasure":"fragments/mL"}